Open AccessIn Vitro Activities of Trioxaquines against Schistosoma mansoni
Author(s) -
Jérôme Boissier,
Frédéric Cosledan,
Anne Robert,
Bernard Meunier
Publication year - 2009
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00640-09
Subject(s) - praziquantel , artesunate , artemisinin , artemether , schistosoma mansoni , schistosomiasis , anthelmintic , in vitro , pharmacology , schistosoma , biology , helminthiasis , traditional medicine , helminths , medicine , immunology , malaria , plasmodium falciparum , zoology , biochemistry
We report the in vitro activities of trioxaquines against larval and adult-stage schistosomes at 5 and 50 microg/ml, respectively. Such activities are equivalent to that of praziquantel, the major and rather unique drug currently used for the treatment of schistosomiasis. In this range of concentrations, artemisinin derivatives (artesunate and artemether) have no activity.